Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Specialized palliative care in patients with haematological malignancies receiving chimeric antigen receptor T-cell therapy.
Eichenauer DA, Heger JM, Kruschel I, Kutsch N, Gödel P, Garcia Borrega J, Schnetzke U, Böll B, Neumann MA, Gebel C, Pralong A, Borchmann P, Voltz R, Wedding U, Simon ST. Eichenauer DA, et al. Among authors: boll b. Br J Haematol. 2024 Mar 24. doi: 10.1111/bjh.19434. Online ahead of print. Br J Haematol. 2024. PMID: 38522848 No abstract available.
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i).
Gillessen S, Hüttmann A, Vucinic V, Müller H, Plütschow A, Viardot A, Topp MS, Kobe C, Böll B, Eichenauer DA, Sasse S, Haverkamp H, Schmitz C, Borchmann S, Bröckelmann PJ, Heger JM, Fuchs M, Engert A, Borchmann P, von Tresckow B. Gillessen S, et al. Among authors: boll b. Br J Haematol. 2022 Feb;196(3):606-616. doi: 10.1111/bjh.17878. Epub 2021 Nov 14. Br J Haematol. 2022. PMID: 34775591 Clinical Trial.
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO).
Gillessen S, Pluetschow A, Vucinic V, Ostermann H, Kobe C, Bröckelmann PJ, Böll B, Eichenauer DA, Heger JM, Borchmann S, Fuchs M, Borchmann P, Engert A, von Tresckow B. Gillessen S, et al. Among authors: boll b. Eur J Haematol. 2022 Dec;109(6):728-735. doi: 10.1111/ejh.13859. Epub 2022 Oct 3. Eur J Haematol. 2022. PMID: 36056778 Clinical Trial.
Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial.
Böll B, Plütschow A, Bürkle C, Atta J, Pfreundschuh M, Feuring-Buske M, Vogelhuber M, Sökler M, Eichenauer DA, Thielen I, von Tresckow B, Fuchs M, Engert A, Borchmann P; German Hodgkin Study Group (GHSG). Böll B, et al. Br J Haematol. 2019 Apr;185(1):42-52. doi: 10.1111/bjh.15741. Epub 2018 Dec 28. Br J Haematol. 2019. PMID: 30592027 Free article. Clinical Trial.
Allogeneic stem cell transplant recipients admitted to the intensive care unit during the peri-transplant period have unfavorable outcomes-results of a retrospective analysis from a German university hospital.
Garcia Borrega J, Heger JM, Koehler P, Holtick U, Hallek M, Scheid C, Böll B, Shimabukuro-Vornhagen A, Kochanek M, Eichenauer DA. Garcia Borrega J, et al. Among authors: boll b. Ann Hematol. 2022 Feb;101(2):389-395. doi: 10.1007/s00277-021-04698-3. Epub 2021 Oct 20. Ann Hematol. 2022. PMID: 34668981 Free PMC article.
Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: a single-center retrospective analysis.
Garcia Borrega J, Böll B, Kochanek M, Naendrup JH, Simon F, Sieg N, Hallek M, Borchmann P, Holtick U, Shimabukuro-Vornhagen A, Eichenauer DA, Heger JM. Garcia Borrega J, et al. Among authors: boll b. Ann Hematol. 2023 Jan;102(1):191-197. doi: 10.1007/s00277-022-05028-x. Epub 2022 Nov 17. Ann Hematol. 2023. PMID: 36394583 Free PMC article.
148 results